Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Preferred Stock Liabilities (2022)

Orchestra BioMed Holdings (OBIO) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $67.7 million as the latest value for Q4 2022.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $67.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $67.7 million, a N/A change, with the full-year FY2022 number at $67.7 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $67.7 million for Q4 2022 at Orchestra BioMed Holdings, roughly flat from $67.7 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $160.1 million in Q2 2022 to a low of $67.7 million in Q3 2022.